Opinion|Videos|November 22, 2023
Nivolumab/Ipilimumab Followed by Dabrafenib/Trametinib in Metastatic Melanoma: Data From the DREAMseq Trial
Author(s)Hussein A. Tawbi, MD, PhD
The phase 3 DREAMseq trial compared initial treatments of combination immunotherapy or BRAF/MEK inhibitors for B-Raf mutated melanoma, showing a 20% overall survival benefit at 2 years for immunotherapy as the first-line treatment.
Advertisement
Episodes in this series
Advertisement
Related to this article
Recap the 4 late-breaking phase 3 trials from ESMO 2026 Presidential Symposium I in melanoma, bladder cancer, small cell lung cancer, and prostate cancer.
Adding the mRNA-based individualized neoantigen intismeran to pembrolizumab reduced the risk of disease recurrence or death by 42% in melanoma.
Advertisement
Advertisement
Trending on Targeted Onc
1
A New Era in Sarcoma Treatment? Dr Banks on the Potential of TIL Therapy
2
FDA Approves Generic Venetoclax Tablets for CLL/SLL and AML
3
Enzalutamide Fails to Improve Survival in High-Risk Prostate Cancer
4
Neoadjuvant Botensilimab/Balstilimab Shows Activity in Colon Cancer
5